Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H19FN6O2 |
Molecular Weight | 394.4023 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | meso |
SHOW SMILES / InChI
SMILES
[H][C@@]12CN(C[C@]1([H])[C@H]2NCC3=NC4=C(C=C3)C=C(F)C=C4)C5=NC=C(C=N5)C(=O)NO
InChI
InChIKey=QRGHOAATPOLDPF-VQFNDLOPSA-N
InChI=1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18+
Molecular Formula | C20H19FN6O2 |
Molecular Weight | 394.4023 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. | 2010 Dec 23 |
|
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | 2011 Jul 14 |
|
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. | 2012 May 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:48:41 GMT 2023
by
admin
on
Sat Dec 16 13:48:41 GMT 2023
|
Record UNII |
YTL7A418KQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
676118
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
||
|
FDA ORPHAN DRUG |
675818
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
||
|
FDA ORPHAN DRUG |
733420
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10911
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
1235859-13-8
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
SUPERSEDED | |||
|
YTL7A418KQ
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
DB15419
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
49857317
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
300000005934
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
1256448-47-1
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
C78475
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY | |||
|
914937-68-1
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
EF-146
Created by
admin on Sat Dec 16 13:48:42 GMT 2023 , Edited by admin on Sat Dec 16 13:48:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |